Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended capivasertib in combination with fulvestrant for inclusion on the MOH List of Subsidised Drugs for HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration following disease recurrence or progression on or after an endocrine-based regimen with or without a cyclin-dependant kinase 4/6 inhibitor (CDK4/6i). The decision was based on the uncertain extent of clinical benefit compared with fulvestrant monotherapy, unfavourable cost effectiveness compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for capivasertib are provided in the Annex.

Guidance_Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration (6 Feb 2026)

PES_Capivasertib in combination with fulvestrant for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN-alteration (6 Feb 2026)